Blog

  • 3I/ATLAS-Like Interstellar Objects Could Kick Start Planet Formation around High-Mass Stars

    3I/ATLAS-Like Interstellar Objects Could Kick Start Planet Formation around High-Mass Stars

    The discovery of 1I/Oumuamua, 2I/Borisov and 3I/ATLAS showed that significant numbers of interstellar objects populate interstellar space. Their omnipresence means that such objects also reside in protoplanetary disks, which are the reservoir…

    Continue Reading

  • Talha Badar: Current Prognostication Models for MDS Patients with DDX41 Mutation

    Talha Badar: Current Prognostication Models for MDS Patients with DDX41 Mutation

    Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a paper he co-authored with colleagues published in Leukemia Research:

    “Applicability of current prognostication models for MDS patients with…

    Continue Reading

  • James Bond’s new producer David Heyman says he’s up for the challenge

    James Bond’s new producer David Heyman says he’s up for the challenge

    Lizo MzimbaEntertainment Correspondent, London Film Festival

    Getty Images David Heyman in a black dinner jacket and black bow-tieGetty Images

    David Heyman is co-producing the next Bond film

    One of the producers of the next James Bond film has told BBC News he is “very excited to embrace the challenge” of taking the…

    Continue Reading

  • Akbar Djuraev teases the crowd en route to 110kg gold

    Akbar Djuraev teases the crowd en route to 110kg gold

    Uzbekistan’s Akbar Djuraev couldn’t help but crack a sly smile, as the bar went crashing down on his final attempt at the 2025 IWF World Weightlifting Championships in Førde, Norway on Friday (10 October).

    The two-time Olympic weightlifting…

    Continue Reading

  • Journal of Medical Internet Research

    Journal of Medical Internet Research

    The global issue of illicit drug use has worsened, with 292 million users in 2022, a 20% increase over the past decade []. Cannabis is the most widely used illicit drug (228 million), followed by opioids (60 million), cocaine (23 million), and others []. Illicit drug users face various psychological and physiological problems, including mental disorders, cognitive deficits, cardiovascular dysfunction, and blood-borne infections. The social burden is also high, due to links with crime, violence, and sexual abuse []. Treatment is urgently needed, but globally, only about 10% of users receive treatment, a decline since 2015 [].

    Traditional face-to-face psychosocial treatments remain important for illicit drug users but often fail to meet the needs of most patients due to time, location, and social stigma []. The COVID-19 pandemic accelerated the development of telehealth [] and pushed digital interventions from early simple interactions to more complex forms []. Modern digital interventions can provide multiple interaction methods via smart devices, such as apps, websites, email, text messages, video, audio, and computer programs. They overcome the limitations of traditional treatments and are valued for their flexibility and cost-effectiveness [-], better meeting personalized needs and improving treatment engagement []. Meta-analyses show that digital interventions are effective across different populations of illicit drug users [-].

    However, dropout rates are particularly prominent in digital interventions [-]. Meta-analyses indicate that about one-third of individuals with substance use disorders fail to complete treatment [] and only 48% of early dropouts seek help again [], significantly increasing the risk of adverse outcomes [,]. Methodologically, the relatively high dropout rate limits the completeness of research findings, affecting the validity of results and the interpretation of treatment effects []. To improve the accuracy, this study clearly distinguishes three key concepts: engagement refers to behavioral involvement during use []; adherence reflects the alignment between actual behavior and intervention expectations []; while the dropout rate in this study is strictly defined as participants leaving, being lost to follow-up, or stopping participation before the outcome assessment for any reason. This conceptual clarification both distinguishes commonly confused terms and provides a methodological basis for enhancing the effectiveness of digital interventions, with important clinical implications.

    Although the dropout rate is an important outcome indicator of intervention efficacy [], few studies have examined dropout rates among illicit drug users in digital interventions. A meta-analysis published in 2017 was the first to evaluate internet-based interventions in reducing illicit substance use after treatment and follow-up, but dropout rate was not the focus []. Moreover, existing research lacks systematic examination of clinical factors and intervention design, as well as dynamic assessment of dropout patterns at different time points [-], directly limiting the optimization of targeted intervention strategies.

    Based on current research, this study aims to address the gap in dropout rate research in digital interventions. The study compared average dropout rates between the digital intervention and control groups to assess treatment retention under different experimental conditions. It also analyzed how variables at posttreatment and the longest follow-up time points affected dropout rates in the intervention group to support personalized intervention design for different research stages. These findings are important for advancing academic research and expanding clinical applications [].

    Protocol Registration

    This study strictly adheres to the guidelines of the Cochrane Handbook for Interventions [] and is reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines [] (the complete PRISMA checklist is available in ). The research protocol has been registered in the PROSPERO system: CRD42024534389.

    Search Strategy

    To comprehensively and systematically collect relevant literature, this study searched five major databases up to August 27, 2025, including Web of Science, PubMed, PsycINFO, Embase, and the Cochrane Controlled Trials Register. The search strategy combined controlled vocabulary (eg, MeSH terms) and free-text keywords using Boolean operators (“AND” and “OR”). The main search terms included the following: (“digital intervention” OR “internet intervention” OR “e-health” OR “m-health”) AND (“drug abuse” OR “substance use disorder” OR “illicit drugs”) AND (“psychotherapy” OR “psychoeducation” OR “psychodynamic”) AND (“randomized controlled trial” OR “single blind procedure” OR “random sample”). The complete search strategy for each database is provided in .

    Inclusion and Exclusion Criteria

    Inclusion criteria were as follows: (1) Individuals aged 18 years and above with illicit drug use behavior. Illicit drugs refer to controlled substances used for nonmedical or nonscientific purposes, including but not limited to cannabis, cocaine, amphetamines, and opioids []. (2) Digital psychosocial intervention is the primary treatment. Operationally defined as structured psychological intervention primarily delivered through digital platforms, including mobile applications, web-based programs, or digital communication tools, with or without minimal human support. (3) The article must report sample size and dropout rates. (4) Randomized controlled trials. Exclusion criteria were as follows: (1) treatment involving only face-to-face therapy. (2) mixed samples with insufficient proportion of illicit drug users (less than 80%) or without independent subgroup data (eg, alcohol and tobacco users). (3) non-English studies. (4) unpublished reports, study protocols, meta-analyses, reviews, doctoral theses, or other gray literature.

    To ensure the accuracy of literature screening, a dual-screening process was adopted. First, two researchers independently screened the titles and abstracts of retrieved literature to exclude those clearly not meeting inclusion criteria. Subsequently, the full texts of the literature were reviewed for further evaluation. Finally, manual searches were conducted on the reference lists of included studies and related reviews to identify additional studies meeting inclusion criteria. Any disagreements were resolved through discussion.

    Select Variables and Data Extraction

    Outcome Variable

    This study uses the dropout rate from randomized controlled trials as the primary outcome measure. Considering that the influencing factors at different treatment stages may vary [,-], the dropout rate data of the intervention and control groups at the end of treatment and at the longest follow-up time were extracted separately.

    Moderator Variables

    Previous studies have explored the factors influencing dropout among illegal drug users [], but due to differences in confounding variable control methods and insufficient understanding of the complexity of predictive factors, the results have been inconsistent []. Withdrawal from treatment is a dynamic process, and its mechanisms involve complex interactions of multiple factors []. It is difficult to fully explain the complexity of single-variable analysis []. Therefore, this study refers to previous research [] and selects multidimensional variables (): (1) Demographic characteristics of participants: most studies emphasize the role of patient-related variables in predicting dropout [,], and investigating individual differences (such as age, gender, race, digital literacy, etc.) is crucial for developing treatment interventions for specific populations [16]. (2) Baseline clinical characteristics of participants, including the type of illegal drug use, medication patterns, frequency of use, duration of use, and comorbid conditions. Different drugs may have differentiated effects on dropout rates due to their unique pharmacological mechanisms and withdrawal characteristics []. Additionally, the presence of comorbid mental disorders may exacerbate the likelihood of treatment interruption [], which also needs to be considered. (3) Therapist characteristics: the therapeutic orientation and experience level of therapists may be related to patient adherence []. Compared to busy clinic staff, full-time therapists are more likely to invest time and effort to retain and reengage patients who have discontinued treatment [32]. (4) Treatment characteristics: referring to the framework proposed by Derubeis et al [], which focuses on all factors that improve treatment and particularly on the relationship between treatment factors and outcomes. For example, this study extracted personalized feedback, real-time interaction, and therapeutic alliance. The optimization of these modifiable operational variables can directly enhance intervention effectiveness and improve patient treatment adherence [].

    Table 1. Predictor variables.
    Predictor category Variable category Variable Data note
    Demographic characteristics of participants Continuous variable Year Publication year
    N Number of participants
    Age Mean years
    Female Percentage
    White Percentage
    African American Percentage
    Education ≦High school degree (%)
    Employed Percentage
    Unemployed Percentage
    Single/never married Percentage
    Currently single Percentage
    Married/living together Percentage
    Classified variable Developed country Y, N
    Low income Y, NR
    Baseline clinical characteristics of participants Continuous variable Diagnostic Percentage
    Use quantity-pre Mean percentage of substance use quantity in the past 30 days
    Use frequency-pre Mean percentage of substance use frequency in the past 30 days
    Use length-pre Mean length of substance use in years at intake
    Abstinence Percentage
    Classified variable Inclusion criteria Diagnostic and Statistical Manual (DSM) diagnosis, Other
    Comorbid HIV Y, N
    Primary drug use Cocaine, Opioids, Cannabis, ATS, Other
    Therapist characteristics Classified variable Master Y, NR
    Relevant experience Y, NR
    Train Y, NR
    Supervision Y, NR
    Treatment characteristics Continuous variable Session Number of weekly sessions
    Intervention duration Number of weeks
    The longest follow-up Number of weeks
    Classified variable Recruitment Website, Clinic, Community, Campus, Multiple
    Compensation mode Gift certificate, USD
    Compensation Stepped, NR
    Measurement Self-report, Toxicology, Both
    Toxicology Y, N
    Guidance Guided, Unguided
    Personalized feedback/intervention Y, NR
    Real-time interaction Y, NR
    Setting Anywhere, Laboratory
    Delivery Computer, Telephone
    Digital media App, Website
    Digital presentation mode Video, Virtual character
    Fully digital Y, N, NR
    Assessing digital quality Y, NR

    aN: Number.

    b“Employed” and “Unemployed”: Not complementary, they were extracted separately from different studies. We extracted only based on the study reports and did not perform back-extrapolation calculations.

    cDeveloped country: According to the World Health Organization.

    dY: Yes.

    eN: No.

    fNR: Not reported.

    gATS: Amphetamine-type stimulants.

    hUSD: Use USD as experimental compensation.

    iCompensation: Refers to the monetary or nonmonetary rewards provided to study participants for their time and effort.

    jStepped: Refers to a structured payment approach where participants receive partial rewards at different stages (eg, time-based or task-completion).

    Data Extraction

    Two researchers independently extracted data using a predesigned data extraction form. Disagreements were resolved through discussion or consultation with a third researcher. This data extraction form has been piloted in some studies and adjusted according to the recommendations and structured framework of the GRADE manual. For articles that met the inclusion criteria but lacked important data, we contacted the corresponding author via email, and studies that could not provide sufficient data to calculate effect sizes were excluded.

    Quality Assessment

    To assess the bias risk of the included studies, two researchers independently scored each study in five aspects using the revised Cochrane Risk of Bias tool ROB 2.0 []: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Any disagreements were resolved through discussion.

    Statistical Analysis and Software

    We used Comprehensive Meta-Analysis software (CMA 4.0) to synthesize dropout rates across studies []. For each trial, dropout counts and total sample sizes were extracted separately for the intervention and control groups, from which group-specific dropout proportions were calculated. To stabilize variances and account for the bounded nature of proportions, these proportions were transformed into logit event rates with corresponding standard errors, which served as the primary effect size metric. Pooled estimates were calculated separately for intervention and control groups and subsequently back-transformed into raw proportions and expressed as percentages for interpretability, an approach that has been widely applied in meta-analyses of proportion-type outcomes []. Subsequently, between-study heterogeneity was examined using the Q statistic [,] and quantified with the I² statistic []. Given the significant heterogeneity among included studies in outcome measures and moderators [,], all analyses were conducted under a random-effects model []. Publication bias was assessed using funnel plots, Egger’s, Duval and Tweedie’s trim and fill, and Classic fail-safe N tests [], while sensitivity analyses were conducted to evaluate the robustness of the results. To explore potential influencing factors, meta-regression and subgroup analyses were further employed to examine the association between moderators in the intervention group and dropout rate.

    Characteristics of the Included Studies

    After screening relevant articles based on predefined inclusion and exclusion criteria, a total of 41 studies were finally included (see ), involving 9693 participants with an age range of 19 to 50 years. The selection characteristics of the included studies are shown in . The studies included 82 intervention groups, with a total of 48 dropout rate data points, including 18 posttreatment dropout rates and 30 follow-up dropout rates, showing different data results between the two measurement points.

    Figure 1. PRISMA flow diagram of study search and selection. DPI: Digital psychosocial intervention; PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses; RCT: randomized controlled trial.
    Table 2. Selected characteristics of included studies.
    Author (year) Country N Recruitment Primary substance Intervention type Age, M (SD) F (%) Intervention duration
    (wk)
    Sessions The longest follow-up (wk)
    Aharonovich (2012)[] USA 40 Clinic Cocaine/crack (75.8%) MI+BI 45.5 (6.6) 24.2 8 7.00 NR
    Aharonovich (2017a)[] USA 240 Clinic Any MI+BI 46.5 (9.3) 16.3 8.57 7.00 48
    Aharonovich (2017b)[] USA 47 Multiple Crack (91.49%) MI+BI 50.9 (7.0) 23.4 8.57 7.00 NR
    Baumgartner (2021)[] Switzerland, Austria, Germany, Other (0.7%) 575 Website Cannabis (100%) CBT+MI+BI 28.3 (7.9) 29.4 6 NR 12
    Blow (2017)[] USA 780 Clinic Cannabis (91.1%) MI 31.2 (10.9) 55.5 1 1.00 12
    Bonar (2022)[] USA 149 Website Cannabis (100%) CBT+MI 21 (2.2) 55.7 8 7.00 24
    Bonar (2023)[] USA 58 Clinic Cannabis (100%) MI 21.5 (2.4) 65.5 4 7.00 12
    Brooks (2010)[] USA 28 Clinic Cocaine CRA 43.1 (9.2) 55 8 3.00 10
    Buckner (2020)[] USA 63 Campus cannabis BI 19.1 (1.5) 84.1 64 1 2
    Budney (2011)[] USA 38 Community Cannabis (100%) MET+ CBT+CM 32.8 (9.7) 47.1 12 1.00 NR
    Budney (2015)[] USA 75 Multiple Cannabis (100%) MET+ CBT+CM 35.9 (10.5) 43 12 2.00 36
    Campbell (2014)[] USA 507 Clinic Any CRA+CM 34.9 (10.9) 37.9 12 4.00 24
    Carroll (2014)[] USA 101 Clinic Cocaine (100%) CBT 41.9 (9.6) 60.4 8 7.00 24
    Chopra (2009)[] USA 120 Community Opioid (100%) CRA+CM 31.8 (10.5) 42.5 12 3.00 NR
    Christensen (2014)[] USA 170 Multiple Opioid (100%) CRA+CM 34.3 (10.8) 45.9 12 3.00 NR
    Christoff (2015)[] Brazil 458 Campus Any MI 24 (5.4) 7 0.14 1.00 12
    Chun-Hung (2023)[] Taiwan, China 99 Clinic ATS (100%) MBRP 37 (10.4) 18.2 NR 4.20 24
    Conner (2024)[] Canada, USA 781 Campus Cannabis BI 21.7 (2.8) 39.7 0.14 1 4
    Coronado-Montoya (2025)[] Canada 101 Clinic Cannabis (100%) CBT+MI 25.2 (3.9) 18.8 6 1 18
    Dunn (2017)[] USA 76 Clinic Opioid (100%) PE 39.9 (12.7) 40.8 1 1.00 12
    Elliott (2014)[] USA 162 Campus Cannabis (100%) PE 19.3 (1.2) 52 NR NR 4
    Glasner (2022)[] USA 54 Multiple Opioid (50%), ATS (50%) CBT 47.7 (8.2) 20 12 7.00 NR
    Gryczynski (2015)[] USA 360 Clinic Any MI 36.2 (14.6) 46 NR NR 48
    Gryczynski (2016)[] USA 80 Community Any MI 35 (13) 53 1 1.00 24
    Gustafson (2024)[] USA 414 Clinic Opioid PE+BI+MI 37.2 (10.0) 45.2 64 NR 32
    Ingersoll (2011)[] USA 56 Community Crack cocaine (100%) PE 45 (6.4) 51.9 8 0.75 24
    Maricich (2021)[] USA 170 Multiple Opioid (100%) CRA 32.9 (9.8) 45.9 12 2.50 NR
    Marsch (2014)[] USA 160 Community Opioid (100%) CRA+CBT 40.7 (9.8) 25 48 0.54 NR
    Moore (2019)[] USA 82 Clinic Any CBT 42.4 (10.9) 40.2 12 7.00 12
    Olthof (2023)[] Netherlands 378 Website Cannabis (100%) CBT+MI 27.5 (8.5) 30.7 NR NR 24
    Ondersma (2007)[] USA 107 Clinic Any MI 25.1 (5.6) 100 1 1.00 24
    Ondersma (2014)[] USA 143 Clinic Any MI 26.6 (6) 100.0 1 1.00 24
    Schaub (2019)[] Switzerland 311 Website Cannabis (100%) PE+CBT+MI 33.1 (7.6) 27 6 1.50 24
    Schaub (2015)[] Switzerland 308 Multiple Cannabis (100%) CBT+MI 29.8 (10) 24.7 6 NR 12
    Schwartz (2014)[] USA 360 Community Cannabis (88%) BI 36.1 (14.6) 46 1 1.00 12
    Shi (2019)[] USA 20 Community Opioid (100%) CBT 40.5 (12.2) 40 12 6.88 NR
    Sinadinovic (2020)[] Sweden 303 Website Cannabis (100%) PE+CBT+MI 27.4 (7.2) 32.7 6 1.50 12
    Tait (2015)[] Australia 160 Multiple ATS (100%) CBT+MI 22.4 (6.3) 24 NR NR 24
    Tossmann (2011)[] Germany 1292 Website Cannabis (100%) SFBT 24.7 (6.8) 29.5 7.14 NR 12
    Walukevich-Dienst (2019)[] USA 227 Campus Cannabis (100%) PE 19.8 (1.4) 77 NR NR 4
    Xu (2021)[] China 40 Community ATS (>90%) PE+ST 46.1 (9.9) 22.5 NR 1.00 24

    aN: Number of participants.

    bMI: Motivational interviewing.

    cBI: Brief intervention.

    dNR: Not reported.

    eCBT: Cognitive behavior therapy.

    fCRA: Community reinforcement approach.

    gMET: Motivational enhancement therapy.

    hCM: Contingency management.

    iATS: Amphetamine-type stimulants.

    jMBRP: Mindfulness-based relapse prevention.

    kPE: Psychoeducation.

    lSFBT: Solution-focused brief therapy.

    mST: Support.

    Risk of Bias Assessment

    The risk of bias in the included studies was assessed using the Cochrane Risk of Bias tool (ROB 2.0). Detailed results and percentage plots are presented in . The results showed that approximately 90% of the included studies had a low risk in terms of the randomization process (D1), measurement of the outcome (D4), and selection of the reported result (D5). Approximately 55% of the included studies had some concerns about deviations from intended intervention (D2). About 50% of the studies had a high risk of missing outcome data (D3), which is a key focus of our research.

    Meta-Analysis Results

    Posttreatment

    An analysis of 18 studies was conducted using a random-effects model. The main effect results () showed that the mean dropout rate in the intervention group was 22% (95% CI 0.13‐0.36), lower than that in the control group of 26% (95% CI 0.16‐0.39) []. However, heterogeneity testing indicated high variability among the studies (Q=396.18, df=17, P<.001; I²=96%). Further analysis revealed that the variance of the true effect size reached 2.02 (logit units) with a standard deviation of 1.42 (logit units).

    Figure 2. Forest plot of dropout rate in the intervention group at posttreatment [-,,-,,,-,,].

    Meta-regression and subgroup analysis revealed that this extreme variability was primarily due to four variables among three categories (): (1) Participant demographic characteristics: The proportion with employment rate showed a weak positive correlation with dropout rate (OR 1.04, 95% CI 1.00‐1.07; P=.03). (2) Participant clinical characteristics: Participants with baseline clinical diagnoses showed a significant positive correlation with dropout rate (odds ratio [OR] 1.03, 95% CI 1.01‐1.06; P=.01). The dropout rate for those using cocaine as the baseline primary medication (OR 1.96, 95% CI 0.31‐12.57; P=.48) was significantly higher than that for those using cannabis and opioid medications. (3) Intervention characteristics: Intervention frequency showed a significant negative correlation with dropout rate (OR 0.77, 95% CI 0.60‐0.99; P=.04). The other 27 factors showed no significant correlation with dropout rate.

    Table 3. Meta-regressions and subgroup analysis in the intervention group at posttreatment.
    Predictor category Predictor/Predictor value Studies Coefficient Standard error Dropout (95% CI) z-value 2-sided P value
    Demographic characteristics of participants Employed 6 0.0348 0.0159 0.0036 to 0.0661  2.19 .0288
    Baseline clinical characteristics of participants Diagnostic 12 0.0305 0.0125 0.0060 to 0.0549  2.44 .0145
    Primary drug use 17 .0190
    Cocaine 3 0.6738 0.9478 −1.1838 to 2.5314  0.71 .4771
    Opioid 5 −0.2639 0.8303 −1.8912 to 1.3634 −0.32 .7506
    Cannabis 5 −0.7448 0.5838 −1.8889 to 0.3994 −1.28 .2020
    Other 4 −2.2799 0.9056 −4.0548 to −0.5050 −2.52 .0118
    Treatment characteristics Session 17 −0.2609 0.1266 -0.5090 to −0.0127 −2.06 .0394

    The funnel plot showed some studies beyond the expected range (), suggesting the presence of studies with extreme dropout rates. Combined with Egger’s test results (P<.001), this further confirmed the presence of publication bias. After trimming the 5 missing studies on the right side, the effect size was adjusted from 22% to 33%, still not crossing the clinical threshold. Further leave-one-out analysis showed that 366 unpublished studies would need to be included to make the current result statistically insignificant. Overall, the results indicate that despite publication bias, the adjusted effect size did not exceed the clinical threshold and the leave-one-out number was high, supporting the stability of the study conclusions. Sensitivity analysis also showed () that removing any single study would not change the overall trend.

    Figure 3. The funnel plot for dropout rate in the intervention group at posttreatment.
    Figure 4. Sensitivity analysis for dropout rate in the intervention group at posttreatment [-,,-,,,-,,].

    The Longest Follow-Up

    Follow-up analysis of the intervention group was based on 30 studies, with an average dropout rate of 28.2% (95% CI 0.19‐0.39) (), while the rate in the control group was 27.8% (95% CI 0.20‐0.37). However, heterogeneity testing again indicated high variability among the studies (Q=1293.13, df=29, P=.000, I²=98%). Further analysis revealed that the variance of the true effect size reached 1.79 (logit units) with a standard deviation of 1.34 (logit units).

    Figure 5. Forest plot of dropout rate in the intervention group at the longest follow-up [,,-,,,-,-,-,-].

    Meta-regression analysis and subgroup analysis () revealed that this extreme variability is primarily due to 4 variables among three types of characteristics: (1) participant characteristics: dropout rate showed a negative correlation with single status (OR 0.95, 95% CI 0.91‐0.99; P=.01); (2) clinical characteristics: significantly positive correlation with baseline medication frequency (OR 1.18, 95% CI 1.05‐1.32; P=.004); (3) intervention characteristics: participants recruited via website showed a positive correlation with dropout rate (OR 5.74, 95% CI 1.85‐17.76; P=.002), while participants recruited via campus showed a negative correlation with dropout rate (OR 0.28, 95% CI 0.12‐0.66; P=.003); The association between the degree of digitalization and dropout rates varied depending on whether studies with unreported digitalization status (not reported [NR] group) were included. When all studies, including the NR group, were analyzed, the overall model reached statistical significance (Q=28.13, df=2, P<.001), with the NR group showing a strongly significant negative effect (OR 0.16, 95% CI 0.06‐0.41; P<.001). However, when the NR group was excluded and only studies explicitly reporting “fully digital” or “partially digital” were considered, the results were not statistically significant (Q=0.24, P=.62). The other 32 factors showed no significant correlation with dropout rate.

    Table 4. Meta-regression and subgroup analysis in the intervention group at the longest follow-up.
    Predictor category Predictor/Predictor value Studies Coefficient Standard error Dropout (95% CI) z-value 2-sided P value
    Demographic characteristics of participants Currently single 10 −0.0528 0.0214 −0.0947 to −0.0108 −2.47 .0136
    Baseline clinical characteristics of participants Use frequency-pre 10  0.1657 0.0576  0.0528 to 0.2786  2.88 .0040
    Treatment characteristics Recruitment 28
    Website 6  1.7478 0.5762  0.6168 to 2.8770  3.03 .0024
    Clinic 12  0.0973 0.5204 −0.9225 to 1.1172  0.19 .8516
    Campus 5 −1.2797 0.4371 −2.1365 to −0.4230 −2.93 .0034
    Community 5 −0.8413 0.6384 −2.0924 to 0.4099 −1.32 .1875
    Fully digital 30
    No 4  0.5442 0.4530 −0.3437 to 1.4320  1.20 .2297
    Yes 3  0.2858 0.6540 −0.9960 to 1.5676  0.44 .6621
    Not reported 23 −1.8401 0.4882 −2.7970 to −0.8831 −3.77 .0002

    The funnel plot showed some studies beyond the expected range (see ). Combined with Egger test results (P=.023), publication bias was further confirmed. After trimming the six missing studies on the right side, the effect size changed from 28% to 37% after correction, without crossing the clinical threshold. Further leave-one-out sensitivity analysis showed that 1244 unpublished studies would need to be included to make the current results statistically insignificant, supporting the stability of the research conclusion. Meanwhile, sensitivity analysis (see ) indicated that the results of this study were robust and not dependent on individual studies.

    Figure 6. The funnel plot for dropout rate in the intervention group at the longest follow-up.
    Figure 7. Sensitivity analysis for dropout rate in the intervention group at the longest follow-up [,,-,,,-,-,-,-].

    Principal Findings

    This meta-analysis systematically evaluated the treatment retention effect of digital psychosocial interventions among adult illicit drug users. The pooled dropout rate was 22%, slightly lower than the approximately 30% reported for face-to-face psychosocial interventions [], suggesting potential advantages of digital formats for treatment retention. Nevertheless, the substantial heterogeneity across studies limits the generalizability of these findings. Dropout rates also varied across settings and populations. For instance, adults with co-occurring severe mental disorders and substance use had an average dropout of 27% [], whereas clinical samples of opioid users showed rates as high as 41% []. Beyond dropout, adherence constitutes another key indicator of engagement, with evidence showing that participants completed, on average, 60% of digital intervention modules, and only about half finished the full program []. Taken together, these results underscore the importance of considering both dropout and adherence when evaluating intervention effectiveness. Building on this, our moderator analyses further revealed complex interactive effects. To ensure clarity, we retained the classification system established during data extraction, presenting results separately across four major categories of characteristics as well as between short-term and longest intervention stages.

    At the posttreatment stage, dropout was significantly influenced by participants’ demographic, intervention, and clinical characteristics. Regarding demographics, unemployment did not predict dropout, whereas higher employment was unexpectedly associated with greater attrition. This suggests that unstable or high-intensity work may interfere with regular participation. In addition, the short-term income from employment may reduce some patients’ motivation for treatment, especially when symptoms temporarily improve, leading them to discontinue prematurely due to “feeling better” []. For intervention characteristics, intervention frequency showed a negative correlation with dropout, indicating that more frequent contact may help consolidate behavior change, strengthen the therapeutic alliance, and enhance commitment [-]. Future studies should explore the optimal intervention frequency under different conditions [], balancing treatment intensity with patient burden [].

    The results of baseline clinical characteristics indicated that both baseline clinical diagnosis and baseline cocaine use were significantly positively associated with dropout rates. Specifically, patients with a clear baseline diagnosis were at greater risk of dropout due to challenges such as dependency, withdrawal symptoms, and impaired cognitive or emotional functioning []. For this population, the integration of adjunctive pharmacological or behavioral therapies is recommended to reduce dropout []. Furthermore, consistent with previous findings [], participants with baseline cocaine use were more likely to discontinue treatment. Cocaine use disorder is often closely linked to impulsive behavior and diminished adherence []. These substance-specific risks highlight the importance of developing differentiated intervention strategies tailored to distinct types of substance use in future research []. Nevertheless, the small sample size of drug-use subgroups (k≤5) remains a limitation, which could be addressed through multi-institutional collaborations to expand subgroup samples.

    During the longest follow-up, dropout was significantly influenced by demographic, clinical, and intervention characteristics. In demographics, a higher proportion of single participants was linked to lower dropout. This may be related to reduced drug exposure in family environments [-]. In addition, single participants with low social support were more likely to continue seeking health information online. Future research could involve non–drug-using significant others in monitoring the intervention process and integrate peer support modules []. In clinical characteristics, participants with higher baseline drug use frequency faced markedly greater dropout risk. This finding is consistent with recent studies []. For this high-risk group, we recommend the implementation of multistage intensive intervention programs [], together with the development of immediate-response modules (eg, crisis management tools, real-time consultation functions) to reduce early dropout [].

    In terms of intervention characteristics, participants recruited through websites exhibited higher dropout rates, whereas those recruited from campus showed lower dropout rates. This may be explained by the lack of intensive treatment services typically provided in clinical settings, as well as the relative stability of campus environments [,]. Based on this finding, we recommend adopting a mixed online–offline recruitment strategy []. In addition, intervention content should be optimized for online recruits [], including simplifying operational procedures, providing regular reminders, and offering personalized feedback. The study also analyzed the association between the degree of digitalization and dropout rates. During data processing, studies that did not report their digitalization status (23/30, 77%) were categorized separately as a “Not reported” group for analysis rather than being directly excluded. The analysis revealed a significant association: compared to the nonsignificant negative correlation between fully digital interventions and dropout rates, interventions with unreported digitalization status showed a significant negative correlation, while non-fully digital interventions demonstrated a significant positive correlation with dropout rates. However, the reliability of these subgroup comparisons is constrained by the prevalent issue of poorly reported data. When we excluded the “Not reported” studies and repeated the analysis, no significant differences were found between fully digital and partially digital interventions. This suggests that the initial findings were likely confounded by nonrandom reporting bias rather than reflecting true effects, making definitive evaluation difficult. Therefore, these results primarily highlight the urgent need for future research to standardize the reporting of specific digital intervention details in order to more reliably explore the role of digitalization degree and human support in improving retention rates [].

    Research Significance

    This study systematically evaluated the dropout rate and its predictive factors among adult illicit drug users in digital psychological interventions, thereby addressing a critical research gap in the field. Unlike previous studies that primarily focused on demographic characteristics, this analysis incorporated multidimensional predictive variables—including clinical features, therapist-related factors, and intervention characteristics—to establish a more systematic theoretical framework. The identification of eight key predictive factors provides valuable insights for personalized interventions, guiding the development of tailored digital tools for patients at high risk of dropout. Optimization strategies derived from this evidence are expected to substantially reduce dropout rates and enhance intervention effectiveness [].

    Limitations and Future Research

    This study has several limitations. First, few of the included trials provided detailed information on software quality or reasons for dropout, which limited our ability to assess the reasons why participants stopped treatment []. Future studies could combine machine learning methods to predict dropout risk [] and use participant-centered questionnaires to collect data on perceived barriers. Previous research [-] emphasized common reasons for dropout, including technical difficulties, lack of engagement, and perceived ineffectiveness of the intervention. Collaboration with software engineers may help optimize the digital experience and reduce technical-related attrition []. Additionally, methodological improvements, such as combining intention-to-treat analysis with run-in phase dropout screening [,], may provide more refined methods for managing early dropout.

    Second, most of the digital interventions included in the studies adopted limited forms, such as videos, virtual characters, or text messages, and lacked interactive features. Incorporating gamification elements may enhance user engagement [], especially when personalized to individual preferences [,]. Emerging evidence suggests that well-designed therapeutic video games can improve cognitive and mental health outcomes [], even inducing neurobiological changes, including alterations in white matter microstructure [-].

    Finally, many studies did not clearly report key methodological details, such as the degree of digitalization or level of human support. Although we conducted analyses including and excluding the “Not reported” category, the lack of such information led to inconsistent findings, preventing definitive conclusions regarding the impact of digitalization on dropout rates. Future studies should standardize reporting of intervention details, including digitalization and human support, to better understand active components and optimize strategies [,]. Another limitation is the high heterogeneity in the meta-analysis (I²>90%), which may reduce robustness. Despite sensitivity and moderator analyses, some variability remained unexplained, suggesting pooled effects may not apply equally across interventions, populations, or outcomes. Future research should adopt rigorous methodologies, including detailed reporting, preregistration, data sharing, and large-scale RCTs. Individual participant data meta-analyses can further clarify subgroup effects and sources of heterogeneity, improving generalizability [].

    Conclusion

    In summary, this meta-analysis systematically examined dropout rates and their predictive factors in digital psychosocial interventions for adult illicit drug users, aiming to provide a comprehensive picture of the research landscape in this field. The results indicate that both short-term and long-term adherence to interventions are characterized by considerable complexity. In the short term, dropout rates were primarily associated with employment status, baseline clinical diagnoses, baseline primary substance use, and intervention frequency. Over longer follow-up periods, marital status, baseline drug use frequency, and recruitment source emerged as key predictors. These findings suggest the need for further investigation into factors that contradict common assumptions or remain insufficiently reported in the literature, as well as greater standardization in the design, measurement, and reporting of randomized controlled trials to improve research quality. Moreover, more attention should be given to tailoring interventions for specific populations, particularly through the design of intervention functions and modules. Continued exploration in these areas will contribute to better supporting patients’ long-term recovery.

    This work was funded by the Major Program of the National Social Science Foundation of China, under Grant No. 22&ZD187.

    None declared.

    Edited by Yan Zhuang; submitted 21.May.2025; peer-reviewed by Chekwube Obianyo, Mohammad Eghbal Heidari, Oluwadotun Catherine Balogun, Jong Long Guo; final revised version received 12.Sep.2025; accepted 19.Sep.2025; published 10.Oct.2025.

    © Jiayi Li, Xinyi Liu, Xiayu Du, Tingni Mi, Zhihong Ren. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 10.Oct.2025.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.

    Continue Reading

  • AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients

    AstraZeneca today announces a historic agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation.

    At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President’s 31 July letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.

    As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

    AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the Company’s recently announced $50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation.”

    AstraZeneca’s commitment to the US and American patients is further reflected in the Company’s largest single investment in a manufacturing facility to date, where the Company broke ground yesterday in Virginia. This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline. Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.

    The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company’s US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.

    Notes

    AstraZeneca’s agreement with US Government
    This is the second agreement that a pharmaceutical company has made with the US Department of Health and Human Services to lower the cost of medicines for American patients in the past two weeks. Specific terms of this agreement remain confidential.

    AstraZeneca
    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca’s website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.

    Contacts
    For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

    Continue Reading

  • Sarepta to seek approval for gene therapy in rare muscular dystrophy

    Sarepta to seek approval for gene therapy in rare muscular dystrophy

    An experimental gene therapy from Sarepta Therapeutics increased levels of the gene missing in an ultra-rare form of muscular dystrophy, according to data the company presented Friday.

    The company has said it plans to file for approval in the disease, known as limb-girdle muscular dystrophy (LGMD) 2E. That would make it the first approved treatment in LGMD, a broad collection of highly rare diseases that can deprive patients of the ability to walk and in some cases shorten life. But it is likely to face a significant uphill battle. 

    The LGMD 2E therapy relies on the same gene-ferrying virus that Sarepta uses in its other treatments, including its approved gene therapy for Duchenne muscular dystrophy, Elevidys, and experimental gene therapies for several other LGMD subtypes. 

    STAT+ Exclusive Story

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    Continue Reading

  • Conservation Is the Work of Art: How The Lightning Field Made Land Art into Land Management

    Conservation Is the Work of Art: How The Lightning Field Made Land Art into Land Management

    Maya Livio

    Southwest of Black Mesa and north of Cerro Verde, Cibola County, New Mexico, 2015. License: CC0.